Macular degeneration and TA-65

First Randomized, Double-Blind, Placebo-Controlled Study to Show Improved Macular Function in Humans
This study summarizes the findings on macular function from a randomized, double-blind, placebo-controlled study of TA-65® in subjects with early age-related macular degeneration (AMD). Subjects taking TA-65®(500 Units) significantly improved their macular function over a 12 month period, whereas subjects in the placebo group demonstrated decreased macular function. The findings suggest that TA-65® can improve macular function in a statistically and possibly clinically significant manner.

➢ Study participants: 38 men and women (52-83 years old)
➢ All patients diagnosed with early age-related macular degeneration
➢ Study length: 12 months
➢ First study to show statistically significant (p=0.04) improvement of retinal threshold sensitivity to light in humans taking TA-65®:
The placebo group showed an increase in retinal threshold sensitivity
Placebo Group
Increase in retinal threshold sensitivity to light over 12 months
Threshold sensitivity to light UP 0.7%
(Increased threshold indicates impairment in macular function)

While, the group taking 500 Units of TA-65® per day showed an improved light sensitivity threshold after one year
TA-65' Group
Decrease in retinal threshold sensitivity to light over 12 months
Threshold sensitivity to light Down 7.5%
(Lower threshold indicates improvement in macular function)

➢ Published in Clinical Ophthalmology, a PubMed-indexed and peer-reviewed journal [PMID: 26869760]

Please contact us for the full paper on pdf.

Try TA65 100 unit capsules or 250 unit capsules and quote AMD at checkout for 5% discount on your first order. /shop